JP2008500361A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500361A5
JP2008500361A5 JP2007515304A JP2007515304A JP2008500361A5 JP 2008500361 A5 JP2008500361 A5 JP 2008500361A5 JP 2007515304 A JP2007515304 A JP 2007515304A JP 2007515304 A JP2007515304 A JP 2007515304A JP 2008500361 A5 JP2008500361 A5 JP 2008500361A5
Authority
JP
Japan
Prior art keywords
monocyclic
bicyclic
cycloalkenyl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515304A
Other languages
English (en)
Japanese (ja)
Other versions
JP4484928B2 (ja
JP2008500361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018381 external-priority patent/WO2005117910A2/en
Publication of JP2008500361A publication Critical patent/JP2008500361A/ja
Publication of JP2008500361A5 publication Critical patent/JP2008500361A5/ja
Application granted granted Critical
Publication of JP4484928B2 publication Critical patent/JP4484928B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515304A 2004-05-26 2005-05-25 アデノシンa1レセプター・アゴニストとしてのプリン誘導体およびその使用方法 Expired - Fee Related JP4484928B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57480504P 2004-05-26 2004-05-26
US58826304P 2004-07-15 2004-07-15
PCT/US2005/018381 WO2005117910A2 (en) 2004-05-26 2005-05-25 Purine derivatives as adenosine a1 receptor agonists and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010015618A Division JP2010090177A (ja) 2004-05-26 2010-01-27 アデノシンa1レセプター・アゴニストとしてのプリン誘導体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2008500361A JP2008500361A (ja) 2008-01-10
JP2008500361A5 true JP2008500361A5 (cg-RX-API-DMAC7.html) 2009-08-13
JP4484928B2 JP4484928B2 (ja) 2010-06-16

Family

ID=35463332

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007515304A Expired - Fee Related JP4484928B2 (ja) 2004-05-26 2005-05-25 アデノシンa1レセプター・アゴニストとしてのプリン誘導体およびその使用方法
JP2010015618A Pending JP2010090177A (ja) 2004-05-26 2010-01-27 アデノシンa1レセプター・アゴニストとしてのプリン誘導体およびその使用方法
JP2013055535A Pending JP2013116920A (ja) 2004-05-26 2013-03-18 アデノシンa1レセプター・アゴニストとしてのプリン誘導体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010015618A Pending JP2010090177A (ja) 2004-05-26 2010-01-27 アデノシンa1レセプター・アゴニストとしてのプリン誘導体およびその使用方法
JP2013055535A Pending JP2013116920A (ja) 2004-05-26 2013-03-18 アデノシンa1レセプター・アゴニストとしてのプリン誘導体およびその使用方法

Country Status (24)

Country Link
US (3) US7423144B2 (cg-RX-API-DMAC7.html)
EP (2) EP1758596B9 (cg-RX-API-DMAC7.html)
JP (3) JP4484928B2 (cg-RX-API-DMAC7.html)
KR (2) KR101267202B1 (cg-RX-API-DMAC7.html)
CN (1) CN103087133B (cg-RX-API-DMAC7.html)
AT (1) ATE462704T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005249430B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510406A (cg-RX-API-DMAC7.html)
CA (1) CA2567289C (cg-RX-API-DMAC7.html)
CY (1) CY1110159T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005020286D1 (cg-RX-API-DMAC7.html)
DK (1) DK1758596T3 (cg-RX-API-DMAC7.html)
EA (1) EA011826B1 (cg-RX-API-DMAC7.html)
ES (1) ES2343421T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100344T2 (cg-RX-API-DMAC7.html)
IL (1) IL179400A (cg-RX-API-DMAC7.html)
ME (1) ME01072B (cg-RX-API-DMAC7.html)
MX (1) MXPA06013560A (cg-RX-API-DMAC7.html)
NO (1) NO339450B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ551951A (cg-RX-API-DMAC7.html)
PL (1) PL1758596T3 (cg-RX-API-DMAC7.html)
PT (1) PT1758596E (cg-RX-API-DMAC7.html)
RS (1) RS51261B (cg-RX-API-DMAC7.html)
WO (1) WO2005117910A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01072B (me) * 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
CA2581132A1 (en) * 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Purine 5'-carboxamide derivatives and their use as adenosine receptor agonists
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
WO2007111954A2 (en) * 2006-03-23 2007-10-04 Inotek Phamaceuticals Corporation Purine compounds and methods of use thereof
PL2001456T3 (pl) * 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
MX2011011229A (es) * 2009-05-01 2011-11-18 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en los seres humanos.
EP2448953A1 (en) 2009-06-30 2012-05-09 Forest Laboratories Holdings Limited Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thatreof as a2ar agonists
KR20120091049A (ko) * 2009-10-26 2012-08-17 이노텍 파마슈티컬스 코포레이션 안과용 제제 및 이의 제조 방법
JP2013516495A (ja) * 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
CN102933220A (zh) * 2010-03-19 2013-02-13 伊诺泰克制药公司 用于降低眼内压的腺苷a1激动剂与碳酸酐酶抑制剂的组合型组合物
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
CA2792265A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
SMT201700377T1 (it) * 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
GB2582361A (en) * 2019-03-21 2020-09-23 Univ Warwick Adenosine receptor agonists
WO2020253870A1 (zh) * 2019-06-21 2020-12-24 中国人民解放军军事科学院军事医学研究院 具有a2a腺苷受体激动剂活性的6-肼基腺苷类化合物
DE102021120112A1 (de) 2021-08-03 2023-02-09 Bayerische Motoren Werke Aktiengesellschaft Schnittwerkzeug für ein Metallblech und ein Verfahren zum Betreiben eines Schnittwerkzeugs für ein Metallblech

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935635B1 (cg-RX-API-DMAC7.html) * 1970-12-28 1974-09-25
CH563405A5 (cg-RX-API-DMAC7.html) * 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
DE2226295A1 (de) * 1972-05-30 1973-12-20 Henning Berlin Gmbh Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
DE2342479A1 (de) * 1973-08-23 1975-03-13 Merck Patent Gmbh Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
JPS5126882A (en) * 1974-08-21 1976-03-05 Yamasa Shoyu Kk Nukureoshido 55 monosurupponsanesuteruno seizoho
GB2001976B (en) * 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP3020580B2 (ja) 1990-09-28 2000-03-15 株式会社日立製作所 マイクロ波プラズマ処理装置
US5206222A (en) * 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
WO1994002497A1 (en) * 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CN1164122A (zh) 1996-03-01 1997-11-05 株式会社日立制作所 等离子处理机及其处理方法
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
WO1998050047A1 (en) 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
AU9596698A (en) * 1997-10-15 1999-05-03 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ES2264826T3 (es) 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6440948B1 (en) 1999-06-22 2002-08-27 Cv Therapeutics, Inc. Thiophene A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
GB9930071D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
CA2434906C (en) 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
CA2551169A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
ME01072B (me) * 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
WO2007111954A2 (en) * 2006-03-23 2007-10-04 Inotek Phamaceuticals Corporation Purine compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021530451A5 (cg-RX-API-DMAC7.html)
JP2010540525A5 (cg-RX-API-DMAC7.html)
ME01005B (me) MONOKLONSKA ANTITIJELA KOJA SE VEZUJU ZA HGM-CSF l MEDICINSKI PREPARATI KOJI IH SADRŽE
EP2228064A3 (en) Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
JP2007534702A5 (cg-RX-API-DMAC7.html)
JP2021534108A5 (cg-RX-API-DMAC7.html)
JP2017524735A5 (cg-RX-API-DMAC7.html)
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
JP2004518723A5 (cg-RX-API-DMAC7.html)
JP2015051994A5 (cg-RX-API-DMAC7.html)
JP2008543854A5 (cg-RX-API-DMAC7.html)
JP2010536766A5 (cg-RX-API-DMAC7.html)
JP2013510123A5 (cg-RX-API-DMAC7.html)
CA2595544A1 (en) Compounds having analgesic and/or immunostimulant activity
JP2006515858A5 (cg-RX-API-DMAC7.html)
PE20040728A1 (es) Inhibidores de caspasa
JP2016503799A5 (cg-RX-API-DMAC7.html)
JP2015518880A5 (cg-RX-API-DMAC7.html)
AR035611A1 (es) 2 -azetidinonas sustituidas con azucares, composicion farmaceutica, un kit, uso de dichos compuestos para la fabricacion de medicamentos utiles como agentes hipocolesterolemicos.
JP2009507896A5 (cg-RX-API-DMAC7.html)
CA2393883A1 (en) Salicylamide derivatives
HRP20100344T2 (hr) Derivati purina kao agonisti adenozin a1 receptora i postupci za njihovu uporabu
JP2015528013A5 (cg-RX-API-DMAC7.html)
JP2010535706A5 (cg-RX-API-DMAC7.html)
JP2011508779A5 (cg-RX-API-DMAC7.html)